-+ 0.00%

Innospec Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St·08/07/2025 10:09:15

Listen to the news

Innospec (NASDAQ:IOSP) Second Quarter 2025 Results

Key Financial Results

Revenue: US$439.7m (up 1.1% from 2Q 2024).
Net income: US$23.5m (down 25% from 2Q 2024).
Profit margin: 5.3% (down from 7.2% in 2Q 2024). The decrease in margin was driven by higher expenses.
EPS: US$0.94 (down from US$1.25 in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-history — NasdaqGS:IOSP Earnings and Revenue History August 7th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Innospec Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in the US.

Performance of the American Chemicals industry.

The company's shares are down 3.1% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Innospec, and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.